Dawnrays Pharmaceutical (Holdings) (SEHK:2348) - Prezzo delle azioni, notizie e analisi

2348 Panoramica delle azioni

Dawnrays Pharmaceutical (Holdings) Limited, una holding di investimento, sviluppa, produce e vende farmaci non brevettati nella Cina continentale e a livello internazionale. Maggiori dettagli

2348 analisi fondamentale
Punteggio fiocco di neve
Valutazione	2/6
Crescita futura	0/6
Prestazioni passate	4/6
Salute finanziaria	6/6
Dividendi	4/6

Premi

Il rapporto prezzo/utile ( 3.1 x) è inferiore al mercato Hong Kong ( 9.6 x)

Gli utili sono cresciuti del 27.3% nell'ultimo anno

Analisi del rischio

Elevato livello di guadagni non monetari

Andamento instabile dei dividendi

Dawnrays Pharmaceutical (Holdings) Limited Concorrenti

Jacobson Pharma

SEHK:2633

HK$1.6b

JBM (Healthcare)

SEHK:2161

HK$1.1b

Zhongzhi Pharmaceutical Holdings

SEHK:3737

HK$777.2m

Lee's Pharmaceutical Holdings

SEHK:950

HK$741.9m

Storia dei prezzi e prestazioni

Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per Dawnrays Pharmaceutical (Holdings)
Prezzi storici delle azioni
Prezzo attuale dell'azione	HK$1.23
Massimo di 52 settimane	HK$1.40
Minimo di 52 settimane	HK$1.00
Beta	0.68
1Variazione di 1 mese	-0.81%
Variazione a 3 mesi	11.82%
Variazione di 1 anno	14.95%
3Variazione a 3 anni	-25.00%
Variazione a 5 anni	-10.87%
Variazione dall'IPO	196.39%

Notizie e aggiornamenti recenti

Dawnrays Pharmaceutical (Holdings)'s (HKG:2348) Earnings Might Not Be As Promising As They Seem

Sep 21

Dawnrays Pharmaceutical (Holdings)'s (HKG:2348) Dividend Will Be CN¥0.015

Sep 11

Recent updates

Dawnrays Pharmaceutical (Holdings)'s (HKG:2348) Earnings Might Not Be As Promising As They Seem

Sep 21

Dawnrays Pharmaceutical (Holdings) (HKG:2348) Has Announced A Dividend Of CN¥0.065

Apr 08

Dawnrays Pharmaceutical (Holdings) (HKG:2348) Is Due To Pay A Dividend Of CN¥0.065

Mar 25

Dawnrays Pharmaceutical (Holdings) (HKG:2348) Has Announced A Dividend Of CN¥0.015

Aug 30

Dawnrays Pharmaceutical (Holdings)'s (HKG:2348) Shareholders Will Receive A Bigger Dividend Than Last Year

May 26

Dawnrays Pharmaceutical (Holdings) (HKG:2348) Will Pay A Dividend Of CN¥0.073

Apr 04

Dawnrays Pharmaceutical (Holdings)'s (HKG:2348) Dividend Will Be CN¥0.015

Sep 19

Dawnrays Pharmaceutical (Holdings)'s (HKG:2348) Solid Profits Have Weak Fundamentals

Sep 22

Dawnrays Pharmaceutical (Holdings) (HKG:2348) Will Pay A Dividend Of HK$0.015

Sep 12

Dawnrays Pharmaceutical (Holdings)'s (HKG:2348) Dividend Will Be HK$0.015

Aug 29

Here's How We Evaluate Dawnrays Pharmaceutical (Holdings) Limited's (HKG:2348) Dividend

Feb 28

Would Shareholders Who Purchased Dawnrays Pharmaceutical (Holdings)'s (HKG:2348) Stock Five Years Be Happy With The Share price Today?

Feb 07

Yung Lai Hung Is The Co-Founder & Executive Director of Dawnrays Pharmaceutical (Holdings) Limited (HKG:2348) And They Just Picked Up 34% More Shares

Jan 14

Dawnrays Pharmaceutical (Holdings) Limited's (HKG:2348) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?

Dec 22

What Kind Of Investors Own Most Of Dawnrays Pharmaceutical (Holdings) Limited (HKG:2348)?

Dec 09

Three Things You Should Check Before Buying Dawnrays Pharmaceutical (Holdings) Limited (HKG:2348) For Its Dividend

Nov 23

Rendimenti per gli azionisti

	2348	HK Pharmaceuticals	HK Mercato
7D	-0.8%	-2.0%	-2.7%
1Y	15.0%	-9.4%	10.9%

Ritorno vs Industria: 2348 ha superato il Hong Kong Pharmaceuticals che ha restituito -9.4 % nell'ultimo anno.

Rendimento vs Mercato: 2348 ha superato il mercato Hong Kong che ha restituito 10.9 % nell'ultimo anno.

Volatilità dei prezzi

Is 2348's price volatile compared to industry and market?
2348 volatility
2348 Average Weekly Movement	5.8%
Pharmaceuticals Industry Average Movement	6.9%
Market Average Movement	9.0%
10% most volatile stocks in HK Market	19.0%
10% least volatile stocks in HK Market	4.2%

Prezzo delle azioni stabile: 2348 non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi.

Volatilità nel tempo: La volatilità settimanale ( 6% ) di 2348 è rimasta stabile nell'ultimo anno.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
1995	1,175	Liwei Yu	www.dawnrays.com

Dawnrays Pharmaceutical (Holdings) Limited, una holding di investimento, sviluppa, produce e vende farmaci non brevettati nella Cina continentale e a livello internazionale. Opera in due segmenti: Intermedi e farmaci sfusi e Farmaci finiti. L'azienda offre antibiotici, tra cui intermedi farmaceutici, farmaci sfusi, polveri per iniezioni e antibiotici orali.

Dawnrays Pharmaceutical (Holdings) Limited Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di Dawnrays Pharmaceutical (Holdings) con la sua capitalizzazione di mercato?
2348 statistiche fondamentali
Capitalizzazione di mercato	HK$1.85b
Guadagni(TTM)	HK$605.44m
Ricavi(TTM)	HK$1.16b

3.1x

Rapporto P/E

1.6x

Rapporto P/S

2348 è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Guadagni e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
2348 Conto economico (TTM)
Ricavi	CN¥1.08b
Costo del fatturato	CN¥493.89m
Profitto lordo	CN¥584.78m
Altre spese	CN¥21.68m
Guadagni	CN¥563.11m

Ultimi guadagni dichiarati

Jun 30, 2024

Prossima data di guadagno

n/a

Utile per azione (EPS)	0.37
Margine lordo	54.21%
Margine di profitto netto	52.20%
Rapporto debito/patrimonio netto	5.6%

Come si è comportato 2348 nel lungo periodo?

Vedi performance storica e confronto

Dividendi

6.3%

Rendimento attuale del dividendo

19%

Rapporto di remunerazione

2348 Panoramica delle azioni

Premi

Analisi del rischio

Dawnrays Pharmaceutical (Holdings) Limited Concorrenti

SEHK:2633

HK$1.6b

SEHK:2161

HK$1.1b

SEHK:3737

HK$777.2m

SEHK:950

HK$741.9m

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

Investor sentiment improves as stock rises 16%

Dawnrays Pharmaceutical (Holdings)'s (HKG:2348) Earnings Might Not Be As Promising As They Seem

New major risk - Earnings quality

Dawnrays Pharmaceutical (Holdings) Limited Appoints Yu Liwei as Chief Executive Officer

Dawnrays Pharmaceutical (Holdings)'s (HKG:2348) Dividend Will Be CN¥0.015

Dawnrays Pharmaceutical (Holdings) Limited Announces Resignation of Wu Weixian as Chief Executive Officer

Recent updates

Investor sentiment improves as stock rises 16%

Dawnrays Pharmaceutical (Holdings)'s (HKG:2348) Earnings Might Not Be As Promising As They Seem

New major risk - Earnings quality

Dawnrays Pharmaceutical (Holdings) Limited Appoints Yu Liwei as Chief Executive Officer

Dawnrays Pharmaceutical (Holdings)'s (HKG:2348) Dividend Will Be CN¥0.015

Dawnrays Pharmaceutical (Holdings) Limited Announces Resignation of Wu Weixian as Chief Executive Officer

Upcoming dividend of HK$0.015 per share

First half dividend of HK$0.015 announced

First half 2024 earnings released: EPS: CN¥0.33 (vs CN¥0.17 in 1H 2023)

Dawnrays Pharmaceutical (Holdings) Limited Announces Interim Dividend for the Six Months Ended 30 June 2024, Payable on 03 October 2024, Payable on 03 October 2024

Dawnrays Pharmaceutical (Holdings) Limited to Report First Half, 2024 Results on Aug 23, 2024

Dawnrays Pharmaceutical (Holdings)'s (HKG:2348) Dividend Will Be CN¥0.065

Dawnrays Pharmaceutical (Holdings) Limited Approves to Declare A Final Dividend for the Year Ended 31 December 2023

Upcoming dividend of HK$0.065 per share

Dawnrays Pharmaceutical (Holdings) (HKG:2348) Will Pay A Dividend Of CN¥0.065

Full year 2023 earnings released: EPS: CN¥0.22 (vs CN¥0.24 in FY 2022)

Dawnrays Pharmaceutical (Holdings) Limited, Annual General Meeting, May 24, 2024

Dawnrays Pharmaceutical (Holdings) (HKG:2348) Has Announced A Dividend Of CN¥0.065

Dawnrays Pharmaceutical (Holdings) Limited Proposes Final Dividend for the Year Ended 31 December 2023, Payable on 12 June 2024

Dawnrays Pharmaceutical (Holdings) Limited Proposes Final Dividend for the Year Ended 31 December 2023, Payable on 12 June 2024

Dawnrays Pharmaceutical (Holdings) (HKG:2348) Is Due To Pay A Dividend Of CN¥0.065

Final dividend of HK$0.065 announced

Full year 2023 earnings released: EPS: CN¥0.22 (vs CN¥0.24 in FY 2022)

Dawnrays Pharmaceutical (Holdings) Limited to Report Fiscal Year 2023 Results on Mar 22, 2024

Upcoming dividend of HK$0.015 per share at 7.1% yield

Dawnrays Pharmaceutical (Holdings) (HKG:2348) Has Announced A Dividend Of CN¥0.015

First half 2023 earnings released: EPS: CN¥0.17 (vs CN¥0.12 in 1H 2022)

Dawnrays Pharmaceutical (Holdings) Limited to Report First Half, 2024 Results on Aug 25, 2023

Dawnrays Pharmaceutical (Holdings) Limited Announces the National Medical Products Administration Accepts the New Drug Application for Ebronucimab Injection

Dawnrays Pharmaceutical (Holdings)'s (HKG:2348) Shareholders Will Receive A Bigger Dividend Than Last Year

Dawnrays Pharmaceutical (Holdings) Limited Approves Final Dividend for the Year Ended 31 December 2022

Upcoming dividend of HK$0.073 per share at 6.2% yield

Chief Executive Officer recently bought HK$2.6m worth of stock

Dawnrays Pharmaceutical (Holdings) (HKG:2348) Will Pay A Dividend Of CN¥0.073

Full year 2022 earnings released: EPS: CN¥0.24 (vs CN¥0.24 in FY 2021)

Insufficient new directors

Dawnrays Pharmaceutical (Holdings)'s (HKG:2348) Dividend Will Be CN¥0.015

Dawnrays Pharmaceutical (Holdings) Limited(SEHK:2348) dropped from S&P Global BMI Index

Upcoming dividend of HK$0.015 per share

First half 2022 earnings released: EPS: CN¥0 (vs CN¥0.11 in 1H 2021)

Dawnrays Pharmaceutical (Holdings) Limited Announces Interim Semi-Annual Ordinary Dividend for the Six Months Ended 30 June 2022, Payable on 05 October 2022

Dawnrays Pharmaceutical (Holdings) Limited to Report First Half, 2022 Results on Aug 26, 2022

Dawnrays Pharmaceutical (Holdings) Limited Declares Final Dividend for the Year Ended December 31, 2021

Upcoming dividend of HK$0.065 per share

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Insufficient new directors

Dawnrays Pharmaceutical (Holdings) Limited, Annual General Meeting, May 27, 2022

Dawnrays Pharmaceutical (Holdings) Ltd Ordinary Shares Deleted from Other OTC

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Dawnrays Pharmaceutical (Holdings) Limited Announces Final Dividend for the Year Ended 31 December 2021, Payable on 15 June 2022

Dawnrays Pharmaceutical (Holdings) Limited Announces Resignation of Chen Shaojun as Executive Director, Effective February 16, 2022

Dawnrays Pharmaceutical (Holdings)'s (HKG:2348) Solid Profits Have Weak Fundamentals

Dawnrays Pharmaceutical (Holdings) (HKG:2348) Will Pay A Dividend Of HK$0.015

Dawnrays Pharmaceutical (Holdings) Limited Announces Initiation of Phase III Clinical Trial for Primary Hypercholesterolemia

First half 2021 earnings released: EPS CN¥0.11 (vs CN¥0.084 in 1H 2020)

Dawnrays Pharmaceutical (Holdings)'s (HKG:2348) Dividend Will Be HK$0.015

CEO & Executive Director recently bought HK$349k worth of stock

Dawnrays Pharmaceutical (Holdings) Limited Approves Special Dividend for the Year Ended 31 December 2020

Upcoming dividend of HK$0.10 per share